Cyberonics, a medical technology company with core expertise in neuromodulation, has appointed Bruce H. KenKnight, Ph.D., as vice president of Emerging Therapies.
KenKnight will lead all of the company's emerging therapies programs, including the current clinical evaluation of autonomic regulation therapy, an emerging therapy for treatment of chronic heart failure that incorporates
Most recently, KenKnight served as president and CEO of Valtech Cardio, a privately-held company developing innovative solutions for surgical and percutaneous mitral valve repair and replacement. From 1990-2010, he worked at Boston Scientific, finally serving as vice president of research and business development for the cardiac rhythm management division. He also has served on the board of directors of seven privately-held companies and serves as associate editor for Cardiovascular Engineering and Technology.